Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that the first four partners have signed on to its new Genedata Screener® Ready-to-Run program for turnkey integrations. Ready-to-Run integrations are instrument-specific, versioned, tested, and maintained by Genedata with the support of the respective instrument companies. Ready-to-Run gives researchers a fast and systematic way to import raw measurements from cutting-edge screening instruments.
Ready-to-Run: Time-savings – Improved User Workflows – Better Science
The Genedata Screener versatile data import APIs enable integration with virtually any plate-based screening instrument, including fluorescence readers, automated high content imagers, automated patch clamp devices, and many more. Due to simple and transparent output formats, standard plate-reader integrations are rather straightforward while other devices producing highly complex, massive-volume data per plate present a host of integration challenges. To address these challenges, the Genedata Screener open integration capability is now standardized with specific integrations of Genedata Screener for instruments from leading vendors including IntelliCyt™, Labcyte™, and Thermo Scientific™. Such integration versions are maintained by Genedata as part of its standard software licensing agreements.
Complex screening instruments create special data acquisition challenges. For example, data import workflows in High-Content Screening (HCS) require specific integrations to select features and to automatically match images to the imported data for immediate single-click display. With Ready-to-Run integrations, researchers simply select the plate results in which they are interested and Genedata Screener conducts the data analysis. Accessing raw instrument data in this manner eliminates time formerly devoted to manual file transfer, increases the power of analysis by importing meta-data, and ultimately gives scientists a better understanding of results.
Genedata Screener, which streamlines and standardizes data analysis, is the only software platform for end-to-end and fully integrated data analysis workflows in screening -- from raw data to the corporate data warehouse. Originally established for HCS, the Genedata Screener standard integration model is packaged in the Ready-to-Run program, which is now extended to High-Throughput Flow and Automated Patch Clamp (APC) technologies as well as liquid handling devices. Nanion Technologies and Genedata have partnered for the first binary integration of an APC instrument with the screening data analysis workflow. Ready-to-Run integrations effectively overcome the gap between drug discovery data flows and data management infrastructure and screening instruments with their software.
“Ready-to-Run is a win-win for Screener customers and our instrument partners,” said Dr. Othmar Pfannes, CEO of Genedata. “Out-of-the-box integration lowers our customers’ total cost of ownership, saves precious time of research IT, and allows researchers to fully leverage their Genedata Screener platform for new technologies. Plus, our instrument partners are now able to easily expand their footprint within the Genedata Screener research community, which includes the world’s leading pharmas, CROs, and academic research institutions.”
The Ready-to-Run program is open to all qualified vendors. Prospective vendors may submit an inquiry to firstname.lastname@example.org.
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial, and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US.
Follow Us on LinkedIn
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.